UR Medicine's Wilmot Cancer Institute | Strategic Alliance Partners

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Molecular markers, risk, and response are being used to better tailor escalated and de-escalated treatment approaches for women with breast cancer.

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.